Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
|
|
- Poppy Carter
- 6 years ago
- Views:
Transcription
1 Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
2 Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended to substitute for the medical judgment of the healthcare provider. Recommendations for use of any particular therapeutic agents or methods are based upon the best available scientific evidence and clinical guidelines. Reference in this activity to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation. Disclosures: I have disclaimers and have served in the following roles: Advisory board: -Millennium Pharmaceuticals Speaker s Bureau: -Millennium Pharmaceuticals -Celgene Pharmaceuticals -Onyxx Pharmaceuticals
3 Faculty Biography Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Clinical Hematology/Oncology Specialist Cone Health Adam graduated from the University of North Carolina at Chapel Hill with a bachelor s degree in history and received a doctorate of pharmacy degree from the Campbell University College of Pharmacy and Health Sciences. He completed both his post graduate year one pharmacy practice residency and his second year post graduate residency in hematology/oncology with the Cone Health System. He is a board certified pharmacotherapist and oncology pharmacist by the American College of Clinical Pharmacy. Adam s current role is as an oncology pharmacy manager and clinical hematology/oncology pharmacy specialist with Cone Health. 3
4 Objectives Describe complications of multiple myeloma and adverse events associated with current therapies Discuss the assessment of patient, disease, and treatment specific factors to identify patients at risk for adverse events or complications Identify supportive care strategies to prevent and treat adverse events Recognize communication and collaborative practice techniques to participate in team based supportive care for patients with multiple myeloma
5 History of Multiple Myeloma Blood 2008; 111;
6 Multiple Myeloma
7 US Multiple Myeloma Statistics Statistic N Newly diagnosed cases (2013) 22,350 Deaths 10,170 Prevalence (2010) 77,617
8 Myeloma Demographics
9 Incidence Over Time in the US Myeloma All Cancers
10 Risk Factors of Multiple Myeloma Increasing age Male sex African American race Family history Monoclonal gammopathy of undetermined significance Radiation therapy Chemical Exposure Viral
11 Myeloma Description Multiple myeloma is a B-cell malignancy derived from antibody-producing plasma cells in the bone marrow The proliferation of myeloma cells leads to excessive production of a monoclonal antibody (M-protein) Also leads to adverse events in other organ systems
12 Common Symptoms of Myeloma System Symptoms Common cause(s) Blood Kidneys Fatigue Recurrent infections Nausea and vomiting Confusion Anemia, Treatment Uninvolved Ig Treatment Renal failure Hypercalcemia Renal failure Hypercalcemia Bone Pain Peripheral neuropathy Fractures Nerve compression Treatment
13 Recommended workup Normal SPEP Blood Specimen Chemistry Serum beta-2 microglobulin Albumin LDH Serum free light chains Serum immunoglobulins Myeloma SPEP NCCN Guidelines v Multiple myeloma
14 Recommended Workup Continued Urine Specimen Routine urinalysis Bone Marrow Specimen Bone marrow aspirate and/or biopsy 24 hour urine collection Cytogenetics -- Bone survey NCCN Guidelines v Multiple myeloma
15 Recommended Workup Continued Journal of Clinical Imaging Science 2013, 3:6
16 Various Stages of Myeloma Monoclonal gammopathy of undetermined significance Smoldering myeloma Symptomatic myeloma Serum monoclonal protein Clonal BM plasma cells < 3 g/dl 3 g/dl And/or Presence of serum and/or urinary monoclonal protein < 10% 10% 10% End-organ damage None None CRAB Mayo Clinic Proc. 2013; 88(4):
17 Crab Criteria Must be present for diagnosis of myeloma to be made C = calicum 11.5 mg/dl R = Renal insufficiency: serum creatinine > 2 mg/dl A = Anemia: Hgb < 10g/dL or 2 g/dl below normal B = Bone Lesions: lytic or osteopenic
18 Durie-Salmon Staging System for MM Stage Criteria Myeloma Cell Mass ( cells/m 2 ) I All of the following: Hemoglobin >10 g/dl Serum calcium level <10.5 mg/dl (normal) Normal bone or solitary plasmacytoma on X ray Low M-component production rate: IgG <5 g/dl; IgA <3 g/dl Bence Jones protein <4 g/24 hr <0.6 (low) II Not fitting stage I or III (intermediate) III One or more of the following: Hemoglobin <8.5 g/dl Serum calcium level >12 mg/dl Advanced lytic bone lesions on X ray High M-component production rate: IgG >7 g/dl; IgA >5 g/dl Bence Jones protein >12 g/24 hr >1.2 (high) Subclassification A B Criteria Normal renal function (serum creatinine level <2.0 mg/dl) Abnormal renal function (serum creatinine level 2.0 mg/dl) Cancer 1975;36:842.
19 International Staging System for Multiple Myeloma Stage Laboratory value(s) Stage I Serum β-2 microglobulin < 3.5 mg/dl Serum albumin 3.5 mg/dl Stage II Neither stage I or III values Stage III Serum β-2 microglobulin 5.5 mg/dl Journal of Clinical Oncology 2005;23:
20 Risk stratification in multiple myeloma Risk group Factors Frequency Median Overall Survival High Deletion 17p t(14;16) t(14;20) 20% 3 y Intermediate t(4;14) Cytogenetic del 13 or Hypodiploidy Plasma cell labeling index 20% 4-5 y Standard Hyperdiploid t(11;14) t(6;14) 60% 8-10 y Mayo Clinic Proc. 2013; 88(4):
21 Response Criteria Response Category scr, stringent complete response Response Criteria Normal free light chain ratio and absence of clonal bone marrow by immunofluroesence CR, complete response Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and 5% plasma cells in the bone marrow VGPR, very good partial response Serum and urine M-protein detectable by immunofixation but not on electrophoresis PR, partial response 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by 90% or to < 200 mg per 24 hour SD, stable disease Not meeting criteria for CR, VGPR, PR, or progressive disease Progressive disease Increase of 25% from baseline in various categories Clinical relapse Direct indicators of increasing disease and/or end organ dysfunction (CRAB criteria) NCCN Guidelines v Multiple myeloma
22 FDA Approved Agents Cyclophosphamid e & Melphalan Bortezomib Thalidomide Lenalidomide PLD Carfilzomib Pomalidomide Pre
23 Examples of Myeloma Regimens Regimen BiRD CyBorD MPT RVD Rd VMP Medication Clarithromycin 500 mg bid starting day 2 of cycle 1 Lenalidomide 25 mg qd days 3-21 cycle 1 and days 1-21 subsequent cycles Dexamethasone 40 mg days 1,2,3,8,15, and 22 then weekly Every 4 weeks Cyclophosphamide 300 mg/m2 PO days 1,8,15,22 Bortezomib 1.3 mg/m2 IV once per day on days 1,4,8,11 Dexamethasone days 1-4, 9-12, Every 28 days x 4-12 cycles Melphalan 0.25 mg/kg PO daily days 1-4 Prednisone 2mg/kg PO daily days 1-4 Thalidomide 100 mg PO daily on days 1-28 Every 42 days x 12 cycles Lenalidomide 25 mg daily days 1-14 Bortezomib 1.3 mg/m2 IV days 1,4,8,11 Dexamethasone 20 mg days 1-5,8-9, Every 21 days x 4-8 cycles Lenalidomide 25 mg daily days 1-21 Dexamethasone 40 mg days 1,8,15,22 Every 4 weeks Bortezomib 1.3 mg/m2 every 3 weeks x 8 cycles then days 1, 8 every 3 weeks x 10 cycles Melphalan 9 mg/m2 days 1-4 Prednisone 60 mg/m2 days 1-4
24 Alkylating Agents
25 Proteasome inhibition J Natl Cancer Institute 2011; 103:
26 Proteasome Inhibitor Adverse Effects Neutropenia Thrombocytopenia Cardiac toxicity (minimal) Hepatic toxicity Renal toxicity Peripheral neuropathy Zoster reactivation
27 Immunomodulatory agents
28 Venous Thromboembolism with IMiDs Enhance platelet aggregation Cytokine-mediated disruption Increase in tissue factor activity May cause protein C resistance New England Journal of Medicine 2003; 349:
29 Smoldering Myeloma No symptoms and no related organ or tissue involvement Indolent course Low amounts of M-protein without Significant anemia Hypercalcemia Bone disease
30 Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma 125 patients, High-risk smoldering multiple myeloma R E C E I V E D Lenalidomide 25 mg daily x 21 days every 28 days Observation T I M E T O P R O G R E S S I O N New England Journal of Medicine 2013; 369:
31 Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma New England Journal of Medicine 2013; 369:
32 Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma New England Journal of Medicine 2013; 369:
33 Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma New England Journal of Medicine 2013; 369:
34 Initial Therapy of Multiple Myeloma Remains a challenge Numerous options and combinations available Factors that may influence therapy Availability of agents Comfort of treating provider Consensus among experts Individual patient
35 Standard of care by setting Transplant eligible Induction ASCT +/- Maintenance Newly Diagnosed Myeloma Transplant ineligible Induction Maintenance NCCN Guidelines v Multiple myeloma
36 Transplant-Eligible Patients First step is to evaluate patient Mayo clinic consider patients with a physiologic age of 70 years old for ASCT Patients who undergo ASCT generally receive 4 cycles Intent of therapy is to have achieved at least a partial response prior high-dose therapy Combination induction regimens vary widely High-dose chemotherapy with autologous stem cell support Mayo Clinic Proc. 2013; 88(4):
37 Transplant-Eligible Patients Bortezomib/dexamethasone Bortezomib/cyclophosphamide/ dexamethasone Primary Therapy for Transplant Candidates Bortezomib/doxorubicin/ dexamethasone Bortezomib/lenalidomide/ dexamethasone Bortezomib/thalidomide/ dexamethasone Lenalidomide/dexamethasone NCCN Guidelines v Multiple myeloma
38 Transplant-Eligible Patients Mayo Clinic Proc. 2013; 88(4):
39 Transplant-Eligible Patients Mayo Clinic Proc. 2013; 88(4):
40 Bortezomib Induction and Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Journal of Clinical Oncology 2012; 30:
41 Bortezomib Induction and Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Journal of Clinical Oncology 2012; 30:
42 Bortezomib Induction and Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Peripheral neuropathy First year of treatment VAD = 18% PAD = 40% Newly developed grade 3-4 PNP Thalidomide = 8% Bortezomib = 5% Journal of Clinical Oncology 2012; 30:
43 614 patients, Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma Post-ASCT performed within 6 months Lenalidomide 25 mg daily on days 1-21 every 28 days x 2 cycles R A N D O M Z E D Lenalidomide 10 mg daily x 3 months then increased to 15 mg if tolerated Placebo P R O G R E S S I O N F R E E S U R V I V A L New England Journal of Medicine 2012; 366:
44 Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma HR = 0.50; P<0.001 New England Journal of Medicine 2012; 366:
45 Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma HR = 1.25; P= 0.29 New England Journal of Medicine 2012; 366:
46 Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma New England Journal of Medicine 2012; 366:
47 Transplant-Ineligible Patients Not able to withstand high dose regimens with ASCT Can be treated with similar regimens as transplant eligible patients Increasing agents and regimens becoming available in this setting
48 Transplant-Ineligible Patients Bortezomib/dexamethasone Primary Therapy for Non-Transplant Candidates Lenalidomide/low dose dexamethasone Bortezomib/melphalan/ prednisone Melphalan/lenalidomide/ Prednisone Melphalan/prednisone/thalidomide NCCN Guidelines v Multiple myeloma
49 VISTA Trial 682 patients, Newly diagnosed, untreated, symptomatic Not transplant eligible R A N D O M Z E D Bortezomib Melphalan Prednisone Melphalan Prednisone D I S E A S E P R O G R E S S I O N New England Journal of Medicine 2008; 359:
50 VISTA Trial New England Journal of Medicine 2008; 359:
51 VISTA Trial New England Journal of Medicine 2008; 359:
52 Relapsed, Refractory Disease Retreat with primary regimen if > 6 months Can use numerous combination regimens Most newer FDA approved agents have stipulation that patients must have been treated with Bortezomib Immunomodulatory agent
53 Proteasome inhibition J Natl Cancer Institute 2011; 103:
54 Carfilzomib (Kyprolis) Cycle 1 20 mg/m2 Week 1 Week 2 Week 3 Week 4 Day 1 Day 2 Day 3-7 Day 8 Day 9 Day Day 15 Day 16 Day Day No No No No Cycle 2 and Beyond 27 mg/m2 Week 1 Week 2 Week 3 Week 4 Day 1 Day 2 Day 3-7 Day 8 Day 9 Day Day 15 Day 16 Day Day No No No No * Available as 60 mg single use vial
55 Carfilzomib (Kyprolis ) Dose Modifications Grade 3 or 4 neutropenia Grade 4 thrombocytopenia Cardiac toxicity Hepatic toxicity Renal toxicity Peripheral neuropathy
56 Phase 2 Study of single agent carfilzomib in patients with relapsed and refractory multiple myeloma Prepublished Online Blood
57 Phase 2 Study of single agent carfilzomib in patients with relapsed and refractory multiple myeloma Prepublished Online Blood
58 Phase 2 Study of single agent carfilzomib in patients with relapsed and refractory multiple myeloma Prepublished Online Blood
59 Pomalidomide (Pomalyst ) Dose 4 mg once daily x 21 days every 28 days Dexamethasone 40 mg day(s) 1, 8, 15, 22 every 28 days ( 75 years old) 20 mg day(s) 1, 8, 15, 22 every 28 days (> 75 years old) Dose Modifications Neutropenia Thrombocytopenia Availability Capsules 1 mg 2 mg 3 mg 4 mg
60 Pomalidomide (Pomalyst )
61 Pomalidomide (Pomalyst ) Responsive Outcome Pomalidomide (n = 108) Pomalidomide + LD Dex (n = 113) ORR (CR + PR), % 9 30 CR 0 1 PR 9 29 MR SD PD 16 6 Median Duration of Response, months Median Time to ORR, months NR
62 Proportion of Patients Pomalidomide (Pomalyst ) Median PFS, Mos POM + LoDEX (n = 113) 3.8 POM (n = 108) 2.5 HR: 0.73 P = PFS (Mos) Neutropenia (47%), thrombocytopenia (22%), anemia (22%), leukopenia (6%) were most common hematologic AEs in POM-alone arm Pneumonia (14%), fatigue (10%), back pain (12%), dyspnea (7%) were most common nonhematologic AEs in POM-alone arm
63 Bone Destruction in Myeloma Increased osteoclastic activation Myeloma cells interaction with bone marrow stromal cells Up-regulation of RANKL Osteoprotegrin down regulated Annals of Oncology 2005; 16:
64 Bone Destruction Treatment Bisphosphonates are standard of care Zoledronic acid Pamidronate RANK Ligand inhibitors contraindicated Denosumab
65 Peripheral Neuropathy IV formulation of bortezomib Subcutaneous formulation has shown decreased incidence Carfilzomib has less rates than bortezomib Less observed with newer IMiDs
66 Subcutaneous versus intravenous administration of bortezomib in relapsed multiple myeloma Lancet Oncology 20011; 12:
67 Subcutaneous versus intravenous administration of bortezomib in relapsed multiple myeloma Lancet Oncology 20011; 12:
68 Subcutaneous versus intravenous administration of bortezomib in relapsed multiple myeloma Lancet Oncology 20011; 12:
69 Where We are Headed in Myeloma Optimizing lengths of therapy with agents Using agents approved for relapsed/refractory disease earlier in treatment Newer, novel agents
70 American Society of Hematology Abstracts 2013 Regimen Line of therapy Data to Support Carfilzomib/lenalidomide/ dexamethasone lenalidomide (CRD-R) Newly diagnosed ASH 2013 Carfilzomib/ cyclophosphamide/ dexamethasone (CCd) Newly diagnosed ASH 2013 Carfilzomib/pomalidomide/dex amethasone Refractory ASH 2013 Ixazomib/lenalidomide/ dexamethasone Newly diagnosed ASH 2013 SAR Refractory ASH 2013 Afuresetrib Refactory ASH 2013 Proc ASH 2013: Abstract 538; Proc ASH 2013: Abstract 685; Proc ASH 2013: Abstract 690; Proc ASH 2013: Abstract 535; Proc ASH 2013; Abstract 284; Proc ASH 2013: Abstract 283
71 Team-Based Collaborative Approach Assist providers in dose modifications rather than discontinuing medications Evaluate patients for toxicities Maximize effective supportive care measures to ensure compliance and efficacy Recommend supportive care medications for patients
72 This program has been brought to you by The National Association of Specialty Pharmacy and its education provider The Specialty Pharma Education Center. *All users must complete the post test to receive statement of credit. Credit must be claimed within 30 days of this program.
What do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationPatient Case and Question
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida
More informationDr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationTo learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation
ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus
More informationTreatment options in Myeloma. BritModis myeloma for the elderly care specialist
Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Hans Lee, MD Assistant Professor Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center No Disclosures
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationMultiple Myeloma Patient Handbook
Myeloma Canada Mailing Address: Myeloma Canada 1255 Trans-Canada Highway Suite 160 Dorval, QC H9P 2V4 Telephone: Toll-free: 1-888-798-5771 E-mail: contact@myeloma.ca Multiple Myeloma Patient Handbook Website:
More informationClinical Trials in Multiple Myeloma in Arizona: Past, Present and Future
Clinical Trials in Multiple Myeloma in Arizona: Past, Present and Future AZMN Roundtable March 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Staff
More informationClinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationA Caregiver s Guide to Helping Myeloma Patients. Webinar 1, February 23, 2017 The New Normal for Caregivers of Patients With Multiple Myeloma
A Caregiver s Guide to Helping Myeloma Patients The New Normal for Caregivers of Patients With Multiple Myeloma Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives Discuss use of standard myeloma therapies when used as therapy
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35
Myeloma: diagnosis and management NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationTREATMENT OVERVIEW themmrf.org
MULTIPLE MYELOMA TREATMENT OVERVIEW themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti
More informationMultiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective
Multiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective *Rahman MM, 1 Aziz MA, 2 Islam MM, 3 Zaman AM, 4 Afrose S, 5 Khan MA 6 Treatment of multiple myeloma, a plasma
More informationMultiple myeloma (MM) & related disorders
Multiple myeloma (MM) & related disorders Plasma cell neoplasms Six major variants: (1) Multiple myeloma (2) Solitary plasmacytoma (3) Lymphoplasmacytic lymphoma They secrete a single complete or partial
More informationDenosumab for the prevention of skeletal related events in patients with multiple myeloma first line
NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY
More informationMyeloma. Anne Grace, myeloma survivor. Support for this publication provided by
Myeloma Anne Grace, myeloma survivor Support for this publication provided by Revised 2017 Publication Update Myeloma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique
More informationMultiple Myeloma (MM): Diagnosis, Treatment and Side Effects Management. Transcript. Slide Name & Number
Question 1) Multiple myeloma is a disease of: a) Hematopoietic stem cells b) Reticulocytes c) Plasma cells d) Mature lymphocytes 2) What is the acronym for the criteria used to guide therapy initiation
More informationThe Myeloma Guide Information for Patients and Caregivers
The Myeloma Guide Information for Patients and Caregivers Manuel, myeloma survivor This publication was supported in part by a grant from Revised 2013 A Message From John Walter President and CEO of The
More informationCOMBINATION THERAPY WITH LENALIDOMIDE PLUS DEXAMETHASONE (REV/DEX) FOR NEWLY DIAGNOSED MYELOMA
Blood First Edition Paper, prepublished online August 23, 2005; DOI 10.1182/blood-2005-07-2817 COMBINATION THERAPY WITH LENALIDOMIDE PLUS DEXAMETHASONE (REV/DEX) FOR NEWLY DIAGNOSED MYELOMA S. Vincent
More informationGuidelines for the diagnosis and management of Myeloma within AngCN
Guidelines for the diagnosis and management of Myeloma within AngCN Ref: AngCN-SSG-Ha5 Cancer Standards Measure: N/A Page 1 of 11 Approved and Published: March 2013 1 Introduction These brief guidelines
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016
MYELOMA FORMS The guidelines and figures below are specific to Myeloma studies. The information in this manual does NOT represent a complete set of required forms for any myeloma study. Please refer to
More informationMULTIPLE MYELOMA. on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple
MULTIPLE MYELOMA SANDRA E. KURTIN, RN, MS AOCN, ANP-C Our next session is on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma. Pleased to have here with us today, Ms.
More informationMyeloma Primary Care. Dr R Lovell Feb 2015
Myeloma Primary Care Dr R Lovell Feb 2015 Aims Balance of pathophysiology and cases Explain diagnostic changes (minimal) Staging UK influence Autologous stem cell transplants Primary care myeloma problems
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma December 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma December 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationManaging Your Myeloma
Managing Your Myeloma Managing Your Myeloma Craig Emmitt Cole, MD Assistant Professor of Internal Medicine Multiple Myeloma and Plasma Cell Dyscrasia Program Division of Hematology/Oncology University
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Prof Gordon Cook Professor of Haematology and Myeloma Studies University of Leeds & Leeds Cancer Centre #MyelomaInfodays This talk will cover The
More informationLiving With Myeloma Treatment and Side Effects Management
Slide 1: Welcome & Introductions OPERATOR: Hello, everyone, and welcome to Living With Myeloma Treatment and Side Effects Management, a free telephone/web education program. It is my pleasure to introduce
More informationMyeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation
Myeloma Bone Disease Current and Future Treatment A Publication of The Bone and Cancer Foundation What Is Multiple Myeloma? Multiple Myeloma is a cancer that results from a malignant change in a particular
More informationHematopoietic Stem Cell Transplant in Myeloma. Gary Simmons, DO
Hematopoietic Stem Cell Transplant in Myeloma Gary Simmons, DO Objectives What is the benefit of ASCT What is Upfront therapy and with novel agent era- does it include ASCT Is response before and after
More informationMieloma Múltiplo Tratamento do idoso
Mieloma Múltiplo Mieloma Múltiplo Tratamento do idoso Prof. Dra. Vania Tietsche de Moraes Hungria Professora Adjunta da Disciplina de Hematologia e Oncologia da Faculdade de Ciências Médicas da Santa Casa
More informationThalidomide Therapy. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding Thalidomide Therapy u-thal_en_2017_e1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)
More informationElevated Immunoglobulins and Paraproteins
Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,
More informationUnderstanding. (pomalidomide) capsules. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding POMALYST (pomalidomide) capsules u-pom_en_2017_m3 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873)
More informationFreelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies
Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Montgomery Lobe, MD, and Donald Pasquale, MD Abstract Monoclonal gammopathies are characterized by production of monoclonal
More informationDiagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional
More informationSmouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:
Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.
More informationGSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma
GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma 12 December 2017 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking
More informationImmuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma
Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma Stanley R. Frankel, MD, FACP Corporate Vice President, Clinical R & D Head, Immuno-Oncology Celgene Cancer Progress
More informationUnderstanding MGUS and Smoldering Multiple Myeloma
Multiple Myeloma Cancer of the Bone Marrow Understanding MGUS and Smoldering Multiple Myeloma u-mgus+smm_en_2017_i1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationYour Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results u-ytr_en_2017_h4 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)
More informationTreatment of Multiple Myeloma with Stem Cell Transplantation (SCT)
Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Görgün Akpek, MD, MHS Director, SCT and Cellular Therapy Program Banner MD Anderson Cancer Center GAkpek@mdanderson.org MULTIPLE MYELOMA
More informationFunction, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking
Function, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking Joy Gould BB(ASCP)C, SBB, CQIA(ASQ), CPHQ Thomas Jefferson University Hospital Philadelphia, PA Objectives Define Multiple
More informationFour Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014
Patient Power Knowledge. Confidence. Hope. Toward a Cure for Multiple Myeloma: Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014 Gareth Morgan,
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Craig Emmitt Cole, MD University of Michigan Comprehensive Cancer Center What are Blood Cancers, What IS Multiple Myeloma?
More informationConcise Review. of the Disease and Treatment Options. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Concise Review of the Disease and Treatment Options 2017 Edition Prepared by Brian G.M. Durie, MD A publication of the International Myeloma Foundation Improving
More informationClinico hematological profile of multiple myeloma in tertiary care Hospital, Pune
Original article Clinico hematological profile of multiple myeloma in tertiary care Hospital, Pune Dr. Sagale MS, Dr. Dangmali DP, Dr. Rane SR, Dr. Kulkarni KK, Dr. Puranik SC Department of Pathology,
More informationThis Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed.
MGUS This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed. What is MGUS? Monoclonal gammopathy of undetermined significance, or
More informationFunction, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking
Function, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking Joy Gould BB(ASCP)C, SBB, CQIA(ASQ), CPHQ Thomas Jefferson University Hospital Philadelphia, PA Objectives Define Multiple
More informationManagement of Multiple Myeloma: The Changing Paradigm. Clinical Trials
Management of Multiple Myeloma: The Changing Paradigm Clinical Trials Goal of Clinical Trials: Making Progress Against Myeloma Increase understanding of the disease Improve the way we use currently available
More informationMyeloma 101 Updates and Pain Management Perspectives
Myeloma 101 Updates and Pain Management Perspectives Brian GM Durie, MD Thursday, November 19 th, 2015 Topics for Discussion 1. What to expect from ASH 2015 a preview Research Clinical pearls : New 101
More informationTRANSCRIPT Multiple Myeloma Updates From the 2015 ASCO Annual Meeting and 20 th Congress of EHA
Welcome and Introduction Joan Levy, PhD [Slide 1] Hello everyone! [Slide 2] My name is Joan Levy, and I am Vice President of Research at the Multiple Myeloma Research Foundation (MMRF). I d like to welcome
More informationBrian GM Durie. Black Swan Research Initiative (BSRI) Purpose
Black Swan Research Initiative Brian GM Durie Saturday August 22, 2015 1 Black Swan Research Initiative (BSRI) Purpose The Black Swan Research Initiative (BSRI) is a global collaborative approach Which
More informationDiagnosis and staging
Chapter 2 Diagnosis and staging Carlos Fernández de Larrea and Joan Bladé Diagnostic criteria Multiple myeloma (MM) is a plasma cell disorder characterized by a clonal proliferation of cells producing
More informationHot Topic. Disclosures. None
Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo
More informationNew Treatment Methods in Multiple Myeloma
CLINICAL UPDATE HEMATOLOGY // LABORATORY MEDICINE New Treatment Methods in Multiple Myeloma Szende Jakab 1,2, Erzsébet Lázár 1,2, István Benedek Jr 1,2, Judit Beáta Köpeczi 1, Annamária Pakucs 1, István
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph C l i n i c a l A d v a n c e s i n H e m a t o l o g y & O n c o l o g y A p r i l 2 0 1 2 Emerging Treatment Options for Relapsed and Refractory Multiple Myeloma: A Post-ASH
More informationCAREGIVER GUIDE themmrf.org
MULTIPLE MYELOMA CAREGIVER GUIDE themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_plasma_cell_dyscrasias_multiple_myeloma
More informationLeading Voices. Jonathan Montgomery, Chair of the Health Research Authority (HRA) Patient Experience David Corrin My Myeloma Story
Summer 2016 www.myeloma.org.uk Leading Voices Jonathan Montgomery, Chair of the Health Research Authority (HRA) Patient Experience David Corrin My Myeloma Story Medical MattersMyelo Myeloma NICE guidelines
More informationSelinexor Mechanism of Action
Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone (SPd) in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure Christine
More informationMULTIPLE MYELOMA. A Patients Guide
MULTIPLE MYELOMA A Patients Guide TABLE OF 1. INTRODUCTION...07 2. MYELOMA...09 2.1 What is bone marrow and what does it do? 2.2 What is myeloma? 2.3 What causes myeloma? 2.4 What are the symptoms? 2.5
More informationDo you think you'd be here today if you had not gone to M. D. Anderson?
Advances in Treatment of Multiple Myeloma Webcast November 13, 2007 Michael Wang, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson Cancer Center,
More informationMultiple myeloma is a malignancy
: Diagnosis and Treatment THOMAS C. MICHELS, MD, MPH, and KEITH E. PETERSEN, DO, Madigan Army Medical Center Family Medicine Residency, Tacoma, Washington Multiple myeloma accounts for 1.6% of all cancer
More informationThe Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma
Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 1, August 13, 2015 Antibodies: The Body s Foot Soldiers in the Battle Against Disease Speakers Moderator: Joseph Mikhael,
More informationImmunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
More informationbb2121 for relapsed and refractory multiple myeloma
NIHR Innovation Observatory Evidence Briefing: February 2018 bb2121 for relapsed and refractory multiple myeloma NIHRIO (HSRIC) ID: 19353 NICE ID: 9787 LAY SUMMARY Multiple myeloma (MM) is a rare, incurable
More informationLaboratories and the New IMWG Myeloma Guidelines
Laboratories and the New IMWG Myeloma Guidelines David F. Keren, M.D. Professor of Pathology Division Director, Clinical Pathology The University of Michigan dkeren@med.umich.edu Speaker Disclosure In
More informationTHE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org
THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters
More informationDEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS
DEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS DNB HEALTHCARE CONFERENCE DECEMBER 14 TH, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationPreview of the Medifocus Guidebook on: Multiple Myeloma Updated February 23, 2018
Preview of the Medifocus Guidebook on: Multiple Myeloma Updated February 23, 2018 This document is only a SHORT PREVIEW of the Medifocus Guidebook on Multiple Myeloma. It is intended primarily to give
More informationAn Overview of Chimeric Antigen Receptor T-cells: CAR-T-ing Away Cancer
An Overview of Chimeric Antigen Receptor T-cells: CAR-T-ing Away Cancer Maxwell Brown, PharmD Clinical Pharmacy Manager, Hematopoietic Stem Cell Transplantation NewYork-Presbyterian/Weill Cornell Medical
More informationMicroarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationInfopack for relapsed and/or refractory myeloma patients. Infoline:
Infopack for relapsed and/or refractory myeloma patients. 1 1 What is relapsed myeloma? 2 How will I know if I am relapsing? 3 Can the timing of relapse be predicted? 4 Treatment at relapse 5 Refractory
More informationMinimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing
Minimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing Prof Hervé AVET-LOISEAU, : MD, PhD Institut Universitaire du Cancer Toulouse, France MRD Meta-Analysis in Myeloma Nikhil
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationMeasuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014
Measuring Myeloma in the LAB BL Ferry Clinical Lead Sept 15 th 2014 Oxford Immunology Laboratory Clinical Immunology Churchill WHAT DO WE MEASURE AND HOW? Clinical Immunology Churchill Serum proteins Proteins
More informationGBI Research Report Guidance
THERAPY ANALYSIS Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments Published: July
More informationAddressing THE. Introduction
Addressing THE CURRENT CHALLENGES OF multiple myeloma TREATMENT This CME-certified activity is based on information presented at a satellite symposium held on December 7, 2012, in Atlanta, Georgia. Faculty
More informationMyeloma Bone Disease
Myeloma Bone Disease CURRENT CLINICAL ONCOLOGY Maurie Markman, MD, SERIES EDITOR For other titles published in this series, go to www.springer.com/series/7631 Myeloma Bone Disease Edited by G. David Roodman
More informationPharmaceutical Approvals Monthly
Pharmaceutical Approvals Monthly January 2011 Volume 16 Number 1 Myeloma Foundation Uses Patient Connections To Help Speed Drug Trials Bolstered by a huge patient database, the Multiple Myeloma Research
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 16 June 2005 EMEA/CHMP/94526/2005 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) ANNEX GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
More informationNovel Targets in Multiple Myeloma
Novel Targets in Multiple Myeloma Ajai Chari, MD Abstract Despite the availability of 5 classes of drugs for the treatment of multiple myeloma (MM), the disease remains incurable in most cases, with patients
More informationPanobinostat (Farydak ) and myeloma Myeloma Infoguide Series
Panobinostat (Farydak ) and myeloma Myeloma Infoguide Series Treatments and tests This Infoguide has been made possible thanks to the generosity of Myeloma UK supporters. To find out how you can support
More informationClinical Policy: Eculizumab (Soliris) Reference Number: ERX.SPMN.225
Clinical Policy: (Soliris) Reference Number: ERX.SPMN.225 Effective Date: 01/17 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAdvances in the Biology and Treatment of Myeloma Bone Disease. G. David Roodman MD PhD Indiana University Oct. 22, 2015
Advances in the Biology and Treatment of Myeloma Bone Disease G. David Roodman MD PhD Indiana University Oct. 22, 2015 Relationship between primary molecular cytogenetic abnormalities and specific CRAB
More informationA Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma
MULTIPLE THE IRAQI POSTGRADUATE MYELOMA MEDICAL JOURNAL A Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma Hind Shakir Ahmed ABSTRACT: BACKGROUND: Multiple myeloma (MM) is caused
More informationPublic Assessment Report. Scientific discussion. Bortezomib EBEWE 3.5 mg, powder for solution for injection. (bortezomib) NL/H/3701/001/DC
Public Assessment Report Scientific discussion Bortezomib EBEWE 3.5 mg, powder for solution for injection (bortezomib) NL/H/3701/001/DC Date: 9 May 2017 This module reflects the scientific discussion for
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More information